Neuroendocrine hormones as prognostic biomarkers in the setting of acute stroke: overcoming the major hurdles.
Stroke represents one of the major causes of disability and mortality worldwide and prediction of outcome represents a challenge for both clinicians and researchers. In the past years, many blood markers have been associated with stroke outcome but despite this evidence, no biomarker is routinely used in stroke management. In this review, we focus on markers of the neuroendocrine system, which represent potential candidates to be implemented in clinical practice. Moreover, we present a systematic review and literature-based meta-analysis for copeptin, a new biomarker of the hypothalamo-pituitary-adrenal axis that has shown additional predictive value over clinical information in a large prospective study. The meta-analysis of the included 7 studies, with more than 2000 patients, reinforced its association with poor outcome (pooled odds ratio: 2.474 [1.678-3.268]) and mortality (pooled OR: 2.569 [1.642-3.495]). We further review the current situation of the topic and next steps to implement these tools by clinicians.
['Bustamante|Alejandro|A|', 'Garcia-Berrocoso|Teresa|T|', 'Llombart|Victor|V|', 'Simats|Alba|A|', 'Giralt|Dolors|D|', 'Montaner|Joan|J|']
D015415:Biomarkers D002986:Clinical Trials as Topic D006801:Humans D009490:Neurosecretory Systems D011237:Predictive Value of Tests D011379:Prognosis D020521:Stroke
biomarker stroke outcome systematic review meta-analysis copeptin neuroendocrine marker prognosis